PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Status:
Completed
Trial end date:
2017-11-29
Target enrollment:
Participant gender:
Summary
To estimate the effect of second-line panitumumab monotherapy on objective response in
patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).